KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Cash from Investing Activities (2019 - 2025)

GoodRx Holdings' Cash from Investing Activities history spans 7 years, with the latest figure at -$31.8 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 90.88% year-over-year to -$31.8 million; the TTM value through Dec 2025 reached -$120.0 million, down 70.53%, while the annual FY2025 figure was -$120.0 million, 70.53% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$31.8 million at GoodRx Holdings, down from -$18.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $1.3 million in Q4 2022 and bottomed at -$163.6 million in Q2 2022.
  • The 5-year median for Cash from Investing Activities is -$16.9 million (2024), against an average of -$31.8 million.
  • The largest annual shift saw Cash from Investing Activities tumbled 2601.97% in 2021 before it soared 113.89% in 2022.
  • A 5-year view of Cash from Investing Activities shows it stood at -$9.3 million in 2021, then soared by 113.89% to $1.3 million in 2022, then tumbled by 1100.93% to -$12.9 million in 2023, then decreased by 29.3% to -$16.6 million in 2024, then crashed by 90.88% to -$31.8 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Cash from Investing Activities are -$31.8 million (Q4 2025), -$18.0 million (Q3 2025), and -$18.3 million (Q2 2025).